Article Text

Download PDFPDF

2022-RA-754-ESGO Sentinel lymph node biopsy in endometrial cancer
  1. Cheng Jun Cheong1,
  2. Nicholas Wood2,
  3. Pierre Martin-Hirsch2,
  4. Angelika Kaufmann2 and
  5. Georgios Angelopoulos2
  1. 1University of Manchester, Manchester, United Kingdom
  2. 2Royal Preston Hospital, Preston, United Kingdom


Introduction/Background Sentinel lymph node biopsy (SLNB) is increasingly replacing pelvic lymphadenectomy as part of surgical management of endometrial cancer, due to its high sensitivity and negative predictive value (NPV). This reduces the risks of intra- and post-operative complications. This retrospective service review aims to assess the technique and success rate of SLNB as performed in Royal Preston Hospital.

Methodology 134 patients were identified as having consented for SLNB as part of their surgery to treat endometrial cancer. Data collected included patient demographics, the actual procedure they underwent on both left and right sides, as well as subsequent histopathological findings.

Results SLNB was successful bilaterally in 56% of patients and unilaterally in 74% of patients. 4% of patients underwent bilateral SLNB and pelvic lymphadenectomy, which showed 100% sensitivity and NPV in identifying nodal metastasis.

Conclusion SLNB success rate was lower than equivalent results from more recent studies. However, patient safety was maintained throughout as pelvic lymphadenectomy was performed in instances of SLNB protocol failure.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.